Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership

Stock Track

04/15

3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.

The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.

Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1142533714"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142533714\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142533714?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 11:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142533714","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership","media":"Stock Track","content":"<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 5.12% Intraday on Dual IND Approval for SSS67 and Pfizer Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 11:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.</p><p>The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.</p><p>Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1142533714","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142533714","pubTimestamp":1776225076,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|SSS67与辉瑞合作获双IND批准三生制药盘中大涨5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock price surged 5.12% during intraday trading on Wednesday, marking a significant upward movement.The rally appears driven by positive developments for the company's pipeline. Its independently developed drug candidate SSS67 has officially received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA), following a prior IND clearance from the U.S. Food and Drug Administration (FDA). This represents a key dual-market regulatory milestone for the asset.Further bolstering investor sentiment is the company's landmark partnership with Pfizer, a deal valued at up to over USD 6 billion, which includes a record-setting upfront payment of USD 1.4 billion for a domestically developed innovative drug. Analysts note that southbound capital flows, which were a key driver during the stock's previous major rally, remain a factor to watch.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}